Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Stock Quote Today & Recent News Immunome Inc IMNM

Healthcare Biotechnology
Immunome, Inc., a clinical-stage biotechnology company, develops targeted cancer therapies. The company’s clinical asset comprises Varegacestat, a gamma secretase inhibitor that is in Phase 3 clinical trial for the treatment of desmoid tumors; and IM-1021, a receptor tyrosine kinase-like orphan receptor 1 antibody-drug conjugate (ADC), which is in Phase 1 clinical trial. Its preclinical assets... see more

Current News (NDAQ:IMNM)

Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire 12 days ago

Immunome to Present at 44th Annual J.P. Morgan Healthcare Conference

Business Wire January 6, 2026

Immunome Announces Pricing of Public Offering of Common Stock

Business Wire December 16, 2025

Immunome Announces Proposed Public Offering of Common Stock

Business Wire December 15, 2025

Immunome Announces Positive Topline Results from Phase 3 RINGSIDE Trial of Varegacestat in Patients with Desmoid Tumors

Business Wire December 15, 2025

Immunome to Announce Topline Results from Phase 3 RINGSIDE Trial of Varegacestat in Patients with Desmoid Tumors

Business Wire December 14, 2025

Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire December 4, 2025

Immunome to Present at Upcoming Investor Conferences

Business Wire November 25, 2025

Immunome Reports Third Quarter 2025 Financial Results and Provides Business Update

Business Wire November 6, 2025
View More News ››

Opinion & Analysis (NDAQ:IMNM)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:IMNM)

CAN IMMUNOME BOUNCE BACK FROM CLINICAL HOLD ON IMM-BCP-01

$IMNM   Immunome, Inc. (NASDAQ: IMNM), a biopharmaceutical company, announced the receipt of a clinical hold letter from the U...
AviseAnalytics - January 17, 2022
View more Bullboard ››

Equity Metals Corp.

Equity Metals Corp.

Equity Metals Corporation engages in the acquisition, exploration, and development of mineral and diamond properties in ...
View More »

Podcasts